R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis

34Citations
Citations of this article
67Readers
Mendeley users who have this article in their library.

Abstract

The tumor-associated isocitrate dehydrogenase (IDH) mutants are unique in that they have lost their normal catalytic activity and gained a novel function to produce R-2-hydroxyglutarate (R-2-HG). A recent study now shows that R-2-HG can reversibly promote leukemogenesis in vitro, suggesting a therapeutic potential of targeting mutant IDH1 and IDH2. © 2013 Elsevier Inc.

Cite

CITATION STYLE

APA

Ye, D., Ma, S., Xiong, Y., & Guan, K. L. (2013, March 18). R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell. https://doi.org/10.1016/j.ccr.2013.03.005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free